论文部分内容阅读
目的比较重组人促红细胞生成素每周1次低频率使用以与每周3次高频率使用的效果、安全性。方法维持性血液透析患者60例随机分为两组:实验组30例,采用促红素10000iu/支,皮下注射,1次/周治疗;对照组30例,采用促红素3000Iu/支,皮下注射,3次/周治疗。两组患者治疗间期均为12周。治疗期间观察血常规、血清肝肾功能、电解质、血脂、血压、脉搏、铁蛋白、转铁蛋白饱和度的变化及不良反应。结果实验组总有效率86.67%,对照组总有效率83.33%,两组比较差异无显著意义;治疗前后白细胞、血小板、血脂、肝肾功能、电解质无明显变化;两组不良反应的发生差异无显著意义。结论低频率促红细胞生成素每周1次与高频率促红细胞生成素每周3次治疗肾性贫血的疗效和不良反应,差异无显著性,但减少了注射次数,提高了患者的依从性。
Objective To compare the safety and efficacy of recombinant human erythropoietin once weekly low frequency use with high frequency use three times per week. Methods 60 cases of maintenance hemodialysis patients were randomly divided into two groups: experimental group of 30 cases, the use of erythropoietin 10000iu / branch, subcutaneous injection, 1 / week treatment; control group of 30 patients with erythropoietin 3000Iu / support, subcutaneous Injection, 3 times / week treatment. The duration of treatment in both groups was 12 weeks. Observation of blood routine during treatment, serum liver and kidney function, electrolyte, blood lipids, blood pressure, pulse, ferritin, transferrin saturation changes and adverse reactions. Results The total effective rate was 86.67% in the experimental group and 83.33% in the control group, with no significant difference between the two groups. There was no significant change in the leukocyte, platelet, blood lipid, liver and kidney function and electrolytes before and after treatment. There was no significant difference between the two groups in adverse reactions Significant. Conclusions The efficacy and adverse reactions of low-frequency erythropoietin once per week and high-frequency erythropoietin three times per week for the treatment of renal anemia are insignificant, but the number of injections and the compliance are improved.